Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Holdings Raised by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 409.4% in the third quarter, Holdings Channel reports. The institutional investor owned 1,016,634 shares of the biopharmaceutical company’s stock after acquiring an additional 817,050 shares during the quarter. GSA Capital Partners LLP’s holdings in Marinus Pharmaceuticals were worth $1,789,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Hussman Strategic Advisors Inc. lifted its position in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 10,500 shares in the last quarter. AQR Capital Management LLC lifted its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $34,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Marinus Pharmaceuticals during the 1st quarter valued at $384,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Performance

NASDAQ MRNS opened at $0.34 on Wednesday. The company’s fifty day moving average is $1.31 and its two-hundred day moving average is $1.34. Marinus Pharmaceuticals, Inc. has a 52-week low of $0.26 and a 52-week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter in the prior year, the business earned ($0.61) earnings per share. Research analysts predict that Marinus Pharmaceuticals, Inc. will post -1.92 EPS for the current year.

Analyst Upgrades and Downgrades

MRNS has been the topic of a number of recent research reports. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. StockNews.com started coverage on shares of Marinus Pharmaceuticals in a report on Sunday. They issued a “hold” rating on the stock. Royal Bank of Canada dropped their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.07.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.